125 related articles for article (PubMed ID: 21282741)
21. Lenalidomide: patient management strategies.
Hussein MA
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S22-5. PubMed ID: 16344098
[TBL] [Abstract][Full Text] [Related]
22. Anticoagulation regimens for thalidomide and lenalidomide.
Zangari M
Clin Adv Hematol Oncol; 2006 Sep; 4(9):658-9. PubMed ID: 17099621
[No Abstract] [Full Text] [Related]
23. Novel agents for relapsed and/or refractory multiple myeloma.
Thomas SK; Richards TA; Weber DM
Cancer J; 2009; 15(6):485-93. PubMed ID: 20010168
[TBL] [Abstract][Full Text] [Related]
24. New drugs for multiple myeloma.
Anderson KC
Clin Adv Hematol Oncol; 2006 Aug; 4(8):592-4. PubMed ID: 17099617
[No Abstract] [Full Text] [Related]
25. Lenalidomide for the treatment of B-cell malignancies.
Chanan-Khan AA; Cheson BD
J Clin Oncol; 2008 Mar; 26(9):1544-52. PubMed ID: 18285605
[TBL] [Abstract][Full Text] [Related]
26. Targeting the Wnt/beta-catenin pathway in multiple myeloma.
Schmeel LC; Schmeel FC; Kim Y; Endo T; Lu D; Schmidt-Wolf IG
Anticancer Res; 2013 Nov; 33(11):4719-26. PubMed ID: 24222106
[TBL] [Abstract][Full Text] [Related]
27. Management of the adverse effects of lenalidomide in multiple myeloma.
González Rodríguez AP
Adv Ther; 2011 Mar; 28 Suppl 1():1-10. PubMed ID: 21431626
[TBL] [Abstract][Full Text] [Related]
28. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Dimopoulos M; Spencer A; Attal M; Prince HM; Harousseau JL; Dmoszynska A; San Miguel J; Hellmann A; Facon T; Foà R; Corso A; Masliak Z; Olesnyckyj M; Yu Z; Patin J; Zeldis JB; Knight RD;
N Engl J Med; 2007 Nov; 357(21):2123-32. PubMed ID: 18032762
[TBL] [Abstract][Full Text] [Related]
29. Lenalidomide: a new therapy for multiple myeloma.
Palumbo A; Miguel JS; Sonneveld P; Moreau P; Drach J; Morgan G; Einsele H
Cancer Treat Rev; 2008 May; 34(3):283-91. PubMed ID: 18230411
[TBL] [Abstract][Full Text] [Related]
30. Treatment of tinea versicolor with a new antifungal agent, ciclopirox olamine cream 1%.
Clin Ther; 1985; 7(5):574-83. PubMed ID: 2865009
[TBL] [Abstract][Full Text] [Related]
31. Thalidomide and lenalidomide: Mechanism-based potential drug combinations.
Vallet S; Palumbo A; Raje N; Boccadoro M; Anderson KC
Leuk Lymphoma; 2008 Jul; 49(7):1238-45. PubMed ID: 18452080
[TBL] [Abstract][Full Text] [Related]
32. New drugs for myeloma.
Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
[TBL] [Abstract][Full Text] [Related]
33. [Multiple myeloma -- therapy].
Jung W; Zettl F; Schroers R
Dtsch Med Wochenschr; 2005 Feb; 130(6):283-6; quiz 287-90. PubMed ID: 15692903
[No Abstract] [Full Text] [Related]
34. In vitro efficacy of cinnarizine against lymphoma and multiple myeloma.
Schmeel LC; Schmeel FC; Kim Y; Blaum-Feder S; Endo T; Schmidt-Wolf IG
Anticancer Res; 2015 Feb; 35(2):835-41. PubMed ID: 25667464
[TBL] [Abstract][Full Text] [Related]
35. Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome.
Maier SK; Hammond JM
Ann Pharmacother; 2006 Feb; 40(2):286-9. PubMed ID: 16403850
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of a new antifungal cream, ciclopirox olamine 1% in the treatment of cutaneous candidosis.
Clin Ther; 1985; 8(1):41-8. PubMed ID: 2870809
[TBL] [Abstract][Full Text] [Related]
37. Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma.
Palumbo A; Dimopoulos M; San Miguel J; Harousseau JL; Attal M; Hussein M; Knop S; Ludwig H; von Lilienfeld-Toal M; Sonneveld P
Blood Rev; 2009 Mar; 23(2):87-93. PubMed ID: 18774632
[TBL] [Abstract][Full Text] [Related]
38. [Comparison of the thermostability of natural (sulfoprolamine and sodium usnate) and synthetic (climbazole and piroctone olamine) antidandruff agents].
Coiffard C; Coiffard L; de Roeck-Holtzhauer Y
Ann Pharm Fr; 1999 Sep; 57(5):392-6. PubMed ID: 10520510
[TBL] [Abstract][Full Text] [Related]
39. Lenalidomide: new drug. Myeloma: many questions remain unanswered.
Prescrire Int; 2008 Dec; 17(98):230-2. PubMed ID: 19422142
[TBL] [Abstract][Full Text] [Related]
40. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients.
Morgan GJ; Schey SA; Wu P; Srikanth M; Phekoo KJ; Jenner M; Davies FE
Br J Haematol; 2007 May; 137(3):268-9. PubMed ID: 17408469
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
